Pfizer Inc.'s warnings about the risks of its Zoloft antidepressant were adequate to clear the drugmaker in a second trial over alleged links between the medicine and birth defects (Robinson v. Wolters Kluwer Health, Inc., Pa. Ct. Com. Pl., 14123047, verdict 6/11/14).
A jury in the Pennsylvania Court of Common Pleas June 11 rejected a woman’s claims that Pfizer officials hid the alleged risks.
The verdict may dissuade other Zoloft users from suing over the birth-defect claims. Pfizer faces more than 1,000 such suits.
“This verdict affirms that the Zoloft label contains adequate, science-based information on the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.